Live30 webinars are thirty minute presentations designed to update you on the latest innovations, applications and data in a fast yet interactive format.
As a leader in the development of pancreatic precursor cells for the treatment of Type 1 diabetes, ViaCyte scientists are continuously exploring new technologies to enable expanded scales of culturing human embryonic stem cells (hESCs). Cell therapies hold immense potential to change the lives of patients, but they are limited by production capacity. ViaCyte scientists identified a novel fixed bed bioreactor platform, the Corning® Ascent™ FBR system, as a point of interest due to its capacity for increasing adherent culture scale.
This presentation will review their experience, successfully culturing and expanding hESCs across multiple passages while characterizing for yields and pluripotency. In addition, ViaCyte will discuss some of the general challenges in the field associated with large scale cell therapy manufacturing and how advances such as the Corning Ascent FBR system may impact them.